OrthoPediatrics Corp. delivered a strong enough quarter to move the Street, with the stock up 5.2% on the week to $20.88 and two analyst upgrades in the analysts' notebooks within 24 hours of results — the sharpest burst of analyst activity the name has seen in months.
The Street reaction was swift and constructive. Needham raised its target from $30 to $35 — maintaining a Buy — while Piper Sandler lifted its target from $22 to $25, reiterating Overweight, both actions filed on August 5. Those two moves bracket a consensus picture that has been tilting bullish throughout 2026, with the mean price target now running at $26.67, implying roughly 28% upside from current levels. The bull case rests on Trauma & Deformity growing 17.3%, adjusted EBITDA margins expanding 280 basis points, and management guiding for 12%+ revenue growth in the years ahead. Bears push back on decelerating core segment growth — down to 12.2% in the most recent quarter from 15.7% the prior period — and on sales rep attrition that clouds near-term execution. Truist Securities holds a lone dissenting Hold at a $20 target, keeping the stock priced almost exactly at fair value on that view. EV/EBITDA is running near 17.8x, trending lower over the past month, which gives bulls room to argue the stock still screens reasonably against a sector growing double digits.
Positioning in the lending market tells a relaxed story, with nothing in the borrow data suggesting any meaningful pressure. Short interest is modest at 3.6% of free float — around 907,000 shares — and has edged up roughly 4% over the month without any single-day spike that would flag directional conviction. Borrow availability is generous: 6.6x the shares currently short are still available to lend, well inside the comfortable range and nowhere near stressed territory. Cost to borrow has tumbled nearly 29% over the week to just 0.57% — a near-free borrow rate that signals shorts face no meaningful friction. Options are similarly relaxed, with a put/call ratio of 0.12, marginally above its 20-day average of 0.05 but only about one standard deviation out. There is no evidence of hedging demand building around the print.
One institutional flow worth noting: Granahan Investment Management added 232,760 shares in the most recent filing period, making it one of the more active builders in the register. Wasatch Advisors added 186,357 shares over the same window. On the other side, Millennium Management trimmed 420,069 shares, a meaningful reduction for a fund of that style. The insider side of the register is quiet for now — the most recent trades date to mid-March, when CEO David Bailey and CFO Fred Hite sold modest amounts following equity awards, a routine post-vesting pattern with low significance scores. Insider data is stale beyond 90 days and should be treated as background context rather than a current signal.
Peers tracked a mixed week. TCMD gained 8.7%, outrunning KIDS, while ENOV added 4.5% — comparable moves in a week when orthopedic and medical device names broadly firmed. IART was the outlier, dropping 9.4%, suggesting stock-specific pressures rather than any sector-wide headwind dragging on KIDS. The next scheduled earnings event falls in early November, and between now and then the question is whether management can demonstrate that the deceleration in core segment growth was episodic or marks a structural step-down.
See the live data behind this article on ORTEX.
Open KIDS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
